If they work the same, why choose one over the other? Walk into any med spa in Northern Virginia and you’ll likely be offered Botox. Walk into BeLite Medical Center and you’ll be offered Xeomin. That’s a deliberate choice, and patients ask us about it almost every week. The short answer: the two products deliver
Large amounts of weight loss can improve health dramatically, but patients may also notice changes in their skin, hair, and facial appearance. The popular term “Ozempic face” has made facial-volume loss particularly visible in public discussion, even though these changes may reflect substantial weight loss itself rather than a unique toxic effect of one medication.
Foundayo (orforglipron) brings GLP-1 obesity treatment into a once-daily pill with no food or water restrictions — changing how some patients approach initiation and maintenance therapy.
CagriSema produced 20%+ average weight loss versus placebo — but in the REDEFINE 4 head-to-head it did not prove non-inferior to tirzepatide. Here is what both results mean.
ATTAIN-MAINTAIN found that patients switched from tirzepatide or semaglutide to oral orforglipron preserved substantially more prior weight loss than those switched to placebo.
Bottom line Survodutide, an investigational weekly dual glucagon/GLP-1 receptor agonist, produced significantly greater weight loss than placebo in the Phase 3 SYNCHRONIZE-1 trial. The evidence makes it a credible future obesity treatment, but it is not FDA approved, has no established place relative to Wegovy or Zepbound, and should not be purchased as an
